First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus
Journal
Acta Dermato-Venereologica
Journal Volume
94
Journal Issue
4
Pages
472
Date Issued
2014-07
Author(s)
Abstract
Pemphigus is a life-threatening autoimmune blistering disease. Systemic corticosteroids have been the mainstay and first-line treatment with success. However, longterm use of corticosteroids results in significant morbidities and mortalities. Much effort has been focused on searching alternative or corticosteroids-sparing agents. Rituximab (MabTheraTM; Roche, Basle, Switzerland), a chimeric anti-CD20 monoclonal antibody has been shown to be effective for refractory pemphigus with acceptable side effects (1, 2). Herein, we reported our successful experience with rituximab and corticosteroids as first-line combination therapy for pemphigus.
SDGs
Other Subjects
azathioprine; corticosteroid; prednisolone; rituximab; corticosteroid; immunosuppressive agent; monoclonal antibody; prednisolone; rituximab; absence of side effects; adult; aged; clinical article; corticosteroid therapy; disease severity; drug efficacy; drug safety; female; human; male; middle aged; note; pemphigus foliaceus; pemphigus vulgaris; priority journal; relapse; remission; treatment duration; treatment response; drug combination; immunology; pemphigus; retrospective study; severity of illness index; Taiwan; time; treatment outcome; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pemphigus; Prednisolone; Retrospective Studies; Severity of Illness Index; Taiwan; Time Factors; Treatment Outcome
Publisher
Medical Journals/Acta D-V
Type
note